首页> 中文期刊> 《国际肝胆胰疾病杂志(英文版)》 >Overexpression of anillin is related to poor prognosis in patients with hepatocellular carcinoma

Overexpression of anillin is related to poor prognosis in patients with hepatocellular carcinoma

         

摘要

cqvip:Background: Anillin(ANLN) is required for tumor growth. It has been proven that knockdown of ANLN effectively reduces the occurrence of hepatocellular carcinoma(HCC) in transgenic mice. However, the functional role of ANLN in HCC patients remains to be elucidated. Methods: Both microarray and TCGA project were used for the analyses of ANLN expression and regulation in HCC. The effect of ANLN on proliferation and cell cycle was detected by CCK-8, colony formation assay and flow cytometry. ANLN expression was measured by immunohistochemistry. Correlation between ANLN expression and clinicopathological features was assessed by Pearson Chi-square test and 5-year overall survival after liver resection was evaluated by Kaplan–Meier method. Results: Increased copy number, decreased methylation levels in the Cp G island and upregulated histone hypermethylation of ANLN were found in HCC. Knockdown of ANLN inhibited proliferation and induced G2/M phase arrest in SMMC-7721 cells. ANLN was mainly expressed in the nucleus and showed significantly higher expression levels in cancerous tissues than those in paired adjacent tissues. Moreover, nuclear ANLN expression levels in HCC metastases were significantly higher than those in primary HCC. The results of Cox proportional hazards regression model suggested that ANLN nuclear expression in HCC was an independent risk factor for poor 5-year overall survival of patients after liver resection. Conclusions: ANLN is a potential therapeutic target for HCC. Patients with nuclear ANLN overexpression in HCC tissue may need adjuvant therapy after liver resection.

著录项

  • 来源
    《国际肝胆胰疾病杂志(英文版)》 |2021年第4期|337-344|共8页
  • 作者单位

    Department of Hepatobiliary Surgery Peking University People's Hospital Beijing 100044 China;

    Peking University Institute for Organ Transplantation Beijing 100044 China;

    Beijing Key Laboratory of Liver Cirrhosis and Liver Cancer Beijing 100044 China;

    Department of Hepatobiliary Surgery Peking University People's Hospital Beijing 100044 China;

    Peking University Institute for Organ Transplantation Beijing 100044 China;

    Beijing Key Laboratory of Liver Cirrhosis and Liver Cancer Beijing 100044 China;

    Department of Hepatobiliary Surgery Peking University People's Hospital Beijing 100044 China;

    Peking University Institute for Organ Transplantation Beijing 100044 China;

    Beijing Key Laboratory of Liver Cirrhosis and Liver Cancer Beijing 100044 China;

    Department of Hepatobiliary Surgery Peking University People's Hospital Beijing 100044 China;

    Peking University Institute for Organ Transplantation Beijing 100044 China;

    Beijing Key Laboratory of Liver Cirrhosis and Liver Cancer Beijing 100044 China;

    Department of Pathology Peking University People's Hospital Beijing 100044 China;

    Peking University Institute for Organ Transplantation Beijing 100044 China;

    Beijing Key Laboratory of Liver Cirrhosis and Liver Cancer Beijing 100044 China;

    Peking University Institute for Organ Transplantation Beijing 100044 China;

    Beijing Key Laboratory of Liver Cirrhosis and Liver Cancer Beijing 100044 China;

    Department of Hepatobiliary Surgery Peking University People's Hospital Beijing 100044 China;

    Peking University Institute for Organ Transplantation Beijing 100044 China;

    Beijing Key Laboratory of Liver Cirrhosis and Liver Cancer Beijing 100044 China;

  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号